Five Golden Areas of Single B Cell Technology-Special topic on antibody modification-Tekbiotech-Yeast and Phage Display CRO, Expert in Nano-body and Antibody Drug Development

Five Golden Areas of Single B Cell Technology

Why should antibody screening revolve around the study of B cells? The answer lies in the immune mechanisms of B cells. This technology bypasses the cumbersome processes of hybridoma and directly "captures" native antibodies from human B cells. With its precision, efficiency, and native characteristics, it has become an indispensable core tool in the life sciences.

1. Responding to Emerging Infectious Diseases

In December 2019, the COVID-19 outbreak began. By early 2020, research teams had already isolated single B lymphocytes from the peripheral blood of convalescent patients. Using single B cell sequencing technology and screening, they ultimately obtained antibodies capable of specifically recognizing and neutralizing SARS-CoV-2. Viral mutations progress like a blitzkrieg; traditional hybridoma technology requires 2-3 months to obtain candidate antibodies, making it impossible to keep pace with the speed of viral evolution.

After infection, memory B cells carry the genetic code for "virus-neutralizing antibodies." Single B cell technology directly identifies these memory B cells through "antigen labeling + flow cytometry sorting + single-cell sequencing".

2. Discovery of Antibodies for Cancer Immunotherapy

Tumor-infiltrating B cells (TIL-Bs) are a "hidden force" within the tumor microenvironment. However, traditional methods struggle to isolate the antibodies they secrete—these antibodies may possess the multifunctional capabilities of simultaneously binding tumor antigens, activating complement, and recruiting T cells, making them natural "tumor killers".

Single B cell technology isolates B cells from tumor tissues, labels them with tumor antigens, and sorts antigen-specific B cells.

3. Precise Identification of Pathogenic Antibodies

Autoimmune diseases are caused by autoantibodies mistakenly attacking normal tissues. However, traditional methods struggle to capture rare clones, let alone analyze their evolutionary lineages. Single B cell technology can precisely capture these B cells that produce pathogenic antibodies.

By isolating B cells from the peripheral blood or diseased tissues of patients → analyzing their antibody sequences through single-cell sequencing → identifying pathogenic antibody clones that bind to self-antigens. More importantly, by analyzing the idiotypes of these antibodies, it is possible to design "anti-idiotype" antibodies in reverse to neutralize or eliminate the pathogenic antibodies, thereby achieving therapeutic effects.

4. Precise Assessment of Antibody Protection

The core function of vaccines is to induce highly effective neutralizing antibodies. However, traditional methods can only detect antibody titers and cannot analyze properties such as affinity, epitope coverage, and neutralizing capacity.

Single B cell technology can sort memory B cells in the blood after vaccination, analyze the antibody sequences they carry, and reconstruct the antibody repertoire induced by the vaccine. If "gaps" are found in the antibody repertoire, vaccine antigens can be redesigned in reverse to broaden protection.

It can also screen memory B cells for antibodies with the strongest neutralizing capacity and most critical epitopes. For example, in the development of COVID-19 mRNA vaccines, research teams used single B cell technology to discover that memory B cells just 7 days after vaccination already carried antibodies capable of neutralizing variants—which directly drove the optimization of vaccine booster design.

5. Discovery of Rare Antibodies and Cross-Species Antibodies

For certain special types of antibodies, such as those targeting complex membrane proteins like GPCRs and ion channels, or nanobodies that need to be obtained from special species like camels and sharks, single B cell technology is arguably the only highly efficient method.

TekBiotech (Tianjin) Co., Ltd. has established a comprehensive single B cell antibody discovery platform, dedicated to providing high-quality single B cell antibody development services to scientists worldwide. This platform enables efficient and rapid acquisition of fully human antibodies. We offer one-stop service solutions, providing strong support for our clients' research projects and the development of next-generation therapeutic antibodies targeting refractory disease targets.

References

[1] Cao Y,Su B,Guo X, et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell. 2020;182 (1):73-84.e16.

[2] Ma J,Wu Y,Ma L, et al. A blueprint for tumor-infiltrating B cells across human cancers. Science. 2024;384 (6695):eadj4857.

Previous:How much do you know about ADC drug development? Next:None!